A detailed history of Envestnet Asset Management Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Envestnet Asset Management Inc holds 233,540 shares of NBIX stock, worth $29.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
233,540
Previous 202,793 15.16%
Holding current value
$29.3 Million
Previous $27.9 Million 3.69%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$114.58 - $153.15 $3.52 Million - $4.71 Million
30,747 Added 15.16%
233,540 $26.9 Million
Q2 2024

Aug 08, 2024

BUY
$130.86 - $143.19 $444,400 - $486,273
3,396 Added 1.7%
202,793 $27.9 Million
Q1 2024

May 13, 2024

SELL
$130.4 - $143.74 $24,645 - $27,166
-189 Reduced 0.09%
199,397 $27.5 Million
Q4 2023

Feb 13, 2024

BUY
$106.07 - $132.76 $715,123 - $895,067
6,742 Added 3.5%
199,586 $26.3 Million
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $10.4 Million - $13 Million
110,624 Added 134.55%
192,844 $21.7 Million
Q2 2023

Aug 04, 2023

SELL
$89.53 - $104.87 $29.1 Million - $34 Million
-324,562 Reduced 79.79%
82,220 $7.75 Million
Q1 2023

May 11, 2023

BUY
$94.11 - $123.02 $26.7 Million - $34.9 Million
283,315 Added 229.47%
406,782 $41.2 Million
Q4 2022

Feb 07, 2023

SELL
$106.72 - $127.06 $91,352 - $108,763
-856 Reduced 0.69%
123,467 $14.7 Million
Q3 2022

Nov 10, 2022

SELL
$92.03 - $107.81 $175,133 - $205,162
-1,903 Reduced 1.51%
124,323 $13.2 Million
Q2 2022

Aug 03, 2022

BUY
$75.79 - $100.07 $438,369 - $578,804
5,784 Added 4.8%
126,226 $12.3 Million
Q1 2022

May 04, 2022

BUY
$72.45 - $94.81 $2.57 Million - $3.36 Million
35,452 Added 41.71%
120,442 $11.3 Million
Q4 2021

Feb 04, 2022

SELL
$79.65 - $106.22 $1.05 Million - $1.4 Million
-13,160 Reduced 13.41%
84,990 $7.24 Million
Q3 2021

Oct 07, 2021

BUY
$86.18 - $99.03 $614,204 - $705,786
7,127 Added 7.83%
98,150 $9.41 Million
Q2 2021

Aug 04, 2021

BUY
$89.43 - $102.27 $221,249 - $253,015
2,474 Added 2.79%
91,023 $8.86 Million
Q1 2021

May 04, 2021

BUY
$87.57 - $119.4 $754,940 - $1.03 Million
8,621 Added 10.79%
88,549 $8.61 Million
Q4 2020

Feb 02, 2021

BUY
$86.91 - $108.33 $32,504 - $40,515
374 Added 0.47%
79,928 $7.66 Million
Q3 2020

Oct 09, 2020

BUY
$96.16 - $135.15 $3.11 Million - $4.38 Million
32,384 Added 68.65%
79,554 $7.65 Million
Q2 2020

Jul 08, 2020

BUY
$85.09 - $130.36 $317,215 - $485,982
3,728 Added 8.58%
47,170 $5.76 Million
Q1 2020

Apr 23, 2020

BUY
$75.11 - $113.76 $547,251 - $828,855
7,286 Added 20.15%
43,442 $3.76 Million
Q4 2019

Feb 11, 2020

BUY
$86.8 - $118.57 $87,668 - $119,755
1,010 Added 2.87%
36,156 $3.89 Million
Q3 2019

Oct 17, 2019

BUY
$83.82 - $101.5 $337,543 - $408,740
4,027 Added 12.94%
35,146 $3.17 Million
Q2 2019

Aug 02, 2019

BUY
$72.24 - $91.27 $204,366 - $258,202
2,829 Added 10.0%
31,119 $2.63 Million
Q1 2019

May 10, 2019

BUY
$69.31 - $91.53 $574,371 - $758,509
8,287 Added 41.43%
28,290 $2.49 Million
Q4 2018

Feb 13, 2019

BUY
$68.32 - $124.36 $1.37 Million - $2.49 Million
20,003 New
20,003 $1.43 Million
Q3 2018

Nov 14, 2018

SELL
$98.88 - $125.85 $49,143 - $62,547
-497 Closed
0 $0
Q2 2018

Aug 10, 2018

BUY
$75.3 - $105.99 $6,927 - $9,751
92 Added 22.72%
497 $49,000
Q1 2018

May 09, 2018

BUY
$75.88 - $92.43 $4,021 - $4,898
53 Added 15.06%
405 $34,000
Q4 2017

Feb 20, 2018

SELL
$58.53 - $77.59 $1,463 - $1,939
-25 Reduced 6.63%
352 $27,000
Q3 2017

Nov 13, 2017

SELL
$47.97 - $61.28 $18,516 - $23,654
-386 Reduced 50.59%
377 $23,000
Q2 2017

Aug 14, 2017

BUY
N/A
763
763 $35,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.